REG - Futura Medical PLC - Board change

Futura MedicalAnnouncement

03/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251203:nRSC9582Ja&default-theme=true

RNS Number : 9582J  Futura Medical PLC  03 December 2025

03 December 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

Board change

 

Futura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that
specialises in the development and global commercialisation of innovative and
clinically proven sexual health products, announces that following the passing
of resolutions in respect to the recently announced placing and subscription,
and significant reduction in Lombard Odier Asset Management's percentage
shareholding in Futura following the upcoming admission of the placing shares
and subscription shares to trading on AIM, Harmesh Suniara is stepping down
from his role as Non-Executive Director and will step off the Board with
immediate effect. Harmesh was appointed to the Board as Lombard Odier Asset
Management's representative in March 2025.

 

Andrew Unitt, Non-Executive Chair, commented: "The Board would like to express
our gratitude to Harmesh for his dedication to the Company during his tenure
as Non-Executive Director; his advice and guidance have been invaluable ahead
of the completion of the fundraise. With the successful fundraising in place
giving the Company a sure financial footing, we are now focused on the
competition of the strategic review in Q1 FY26, alongside progressing the
development of Eroxon Intense and WSD4000."

 

Contacts:

 Futura Medical plc                 Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                    Chief Executive Officer

                                                       +44 (0)1483 685 670
                                    Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                    Finance Director and COO

 Panmure Liberum                    Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser                  Rupert Dearden (Corporate Broking)

 and Broker

 Turner Pope Investments (TPI) Ltd  Guy McDougall / Andrew Thacker                          +44 (0) 20 3657 0050

 Broker

 Alma Strategic Communications      Rebecca Sanders-Hewett                                  +44 (0)20 3405 0205

                                    Sam Modlin                                              futura@almastrategic.com

                                    Emma Thompson

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of  ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATTBRTMTTMBJA



            Copyright 2019 Regulatory News Service, all rights reserved